60%+ of physicians now restrict commercial outreach, and most teams respond by sending more. Here's who they really are, how to spot them in data you already have, and the channels that break through.
of physicians place moderate-to-severe restrictions on sales-rep access — up from 35% in 2012
of HCPs are skeptical of the scientific validity of pharma/MedTech communications
Promotion resistance isn't one behavior with one cause. Some physicians opt out on principle and keep a deliberately clean Open Payments record; some are burned out by sheer volume; some are digital-first and self-serve their information. And for a growing share, the block is institutional — they sit inside health systems that limit or bar rep access by policy, from Kaiser Permanente and the VA to Stanford Medicine and many academic medical centers. What unites them isn't disinterest in their field — most stay highly engaged through peers, publications, and conferences. It's that the channel you're using no longer reaches them.
"More than half of U.S. physicians place moderate-to-severe restrictions on sales-rep visits — and access has declined every year since 2008."
ZS AccessMonitor — tracking sales-call records for 400,000+ U.S. prescribers
The channel is wrong, not the relationship. Each unwanted rep touch reinforces the resistance you're trying to overcome — even when the physician is exactly who you want.
We'll tell you what share of your targets are promotion-resistant or hard to reach.
"Low-engagement" hides the fact that several of these segments are high-influence, high-volume clinicians whose adoption decisions move whole departments.
You don't need a survey to find these physicians — the signals are sitting in your CRM, your field reports, and the public Open Payments record. The tells:
Cross-referenced together, these turn "non-responders" into a segmented, addressable list — and tell you which channel each physician will actually answer.
None are free or fast — that's the point. These physicians opted out of fast and free. The channels that work require credibility and patience, and they compound. A 2024 JAMA Health Forum trial showed a single peer-comparison email cut above-guideline opioid prescribing from 37% to 25% across 640 surgeons — with no commercial engagement at all.
Send us your target market, specialty, or CPT/procedure focus. We'll run it against Alpha Sophia's data and tell you what share of your list is genuinely hard to reach — broken into the two drivers:
No cost, no commitment. Send a target list, a specialty, or a CPT/procedure focus — we'll handle the rest.